FERMENTALG (ALGAE.PA)
EUR 0.44
(0.0%)
EUR 0.44
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.05 Million EUR | -46.95% |
| 2022 | 7.64 Million EUR | 35.43% |
| 2021 | 5.64 Million EUR | 156.1% |
| 2020 | 2.2 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.15 Million EUR | 0.0% |
| 2024 Q1 | 3.15 Million EUR | 267.81% |
| 2023 Q4 | 859 Thousand EUR | 0.0% |
| 2023 FY | 4.05 Million EUR | -46.95% |
| 2023 Q3 | 859 Thousand EUR | -26.58% |
| 2023 Q2 | 1.17 Million EUR | 0.0% |
| 2023 Q1 | 1.17 Million EUR | -2.78% |
| 2022 FY | 7.64 Million EUR | 35.43% |
| 2022 Q4 | 1.2 Million EUR | 0.0% |
| 2021 FY | 5.64 Million EUR | 156.1% |
| 2020 FY | 2.2 Million EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nicox S.A. | 257 Thousand EUR | -1478.599% |
| European Medical Solutions | 40.56 Million EUR | 89.999% |
| argenx SE | 1.13 Billion EUR | 99.642% |
| BioSenic S.A. | 543 Thousand EUR | -647.145% |
| Celyad Oncology SA | 102 Thousand EUR | -3877.451% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -94.394% |
| Onward Medical N.V. | 532 Thousand EUR | -662.594% |
| Oxurion NV | 263 Thousand EUR | -1442.586% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -205.958% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.923% |